ERAS News and Press, Erasca Inc. From 12/07/23

2023-12-07 08:27:08 ET MicroAlgo  ( MLGO ) +74% plans to establish a practice base to train graduate students for the university. Altisource Asset Management  ( AAMC ) +23% Asset case against six defendants in suit v. BlackRock, Pimco can proceed. ...

Gained alignment with global health authorities for pivotal Phase 3 SEACRAFT-2 trial design for naporafenib plus trametinib in NRAS mutant melanoma; initiation on track for H1 2024 Completed dose escalation and identified MTD for ERAS-801, supporting enrollment of expansion cohorts in r...

2023-11-17 17:01:57 ET Gainers: Cogent Biosciences ( COGT ) +3% . Erasca ( ERAS ) +3% . Vigil Neuroscience ( VIGL ) +3% . 2seventy  ( TSVT ) +2% . Twist Biosciences ( TWST ) +2% . Losers: Nkarta ( NKTX ) -5% ...

2023-11-09 17:36:00 ET More on Erasca Seeking Alpha’s Quant Rating on Erasca Historical earnings data for Erasca Financial information for Erasca For further details see: Erasca GAAP EPS of -$0.20 beats by $0.01

First patient dosed in SEACRAFT-1 Phase 1b trial evaluating naporafenib plus trametinib Multiple upcoming catalysts across ongoing clinical programs Strong balance sheet with cash, cash equivalents, and marketable securities of $344 million as of September 30, 2023 SAN DIEGO...

SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancer, today announced that management will participate in ...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Erasca Inc. (ERAS) is expected to report $-0.21 for Q3 2023

2023-10-10 15:56:06 ET Shares of Erasca (NASDAQ: ERAS) were up more than 12% as of 3 p.m. on Tuesday after a big insider buy. The healthcare company's stock is down more than 43% this year. Erasca is a clinical-stage precision oncology company that focuses on RAS/MAPK pathwa...

2023-10-10 13:49:05 ET More on Erasca Seeking Alpha’s Quant Rating on Erasca Historical earnings data for Erasca Financial information for Erasca For further details see: Erasca Chairman & CEO acquires stake worth $2.03M